SCHEMBL1115552

SCHEMBL1115552

Cc1nc2cc(Cl)c(N)cc2s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.59
NPC1 O15118 5/20 0.59
RAB9A P51151 5/20 0.59
ALDH1A1 P00352 4/20 0.59
MAPT P10636 3/20 0.59
PKM P14618 2/20 0.59
HPGD P15428 2/20 0.59
TP53 P04637 2/20 0.59
HSD17B10 Q99714 2/20 0.59
GAA P10253 3/20 0.55
TDP1 Q9NUW8 3/20 0.52
KDM4E B2RXH2 2/20 0.52
KMT2A Q03164 2/20 0.52
ATM Q13315 2/20 0.52
HTT P42858 2/20 0.52
MEN1 O00255 1/20 0.52
POLB P06746 1/20 0.52
ALOX15 P16050 1/20 0.45
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30753200 1.00 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL30423025 0.84 SMN1; SMN2 (0.68) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL8653076 0.84 SMN1; SMN2 (0.68) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL617940 0.81 GAA (0.70) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL25424041 0.79 ATM (0.58) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL21882016 0.78 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL30626919 0.78 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL15688913 0.78 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL25424052 0.78 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL4384430 0.77 SMN1; SMN2 (0.85) SMN1; SMN2NPC1RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117088869-A 3CL protease inhibitor and preparation method and application thereof 上海翊石医药科技有限公司 2023-11-21 CN disclosed
US-11518764-B2 Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-12-06 US disclosed
US-20200331921-A1 INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2020-10-22 US disclosed
WO-2019153080-A1 INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2019-08-15 WO disclosed
US-8262949-B2 Long wavelength shifted benzotriazole uv-absorbers and their use BASF SE (DE) 2012-09-11 US disclosed
US-8262949-B2 Long wavelength shifted benzotriazole uv-absorbers and their use BASF SE (DE) 2012-09-11 US disclosed
US-8262949-B2 Long wavelength shifted benzotriazole uv-absorbers and their use BASF SE (DE) 2012-09-11 US disclosed
EP-2032577-B1 LONG WAVELENGTH SHIFTED BENZOTRIAZOLE UV-ABSORBERS AND THEIR USE BASF SE (DE) 2011-02-02 EP disclosed
EP-2032577-B1 LONG WAVELENGTH SHIFTED BENZOTRIAZOLE UV-ABSORBERS AND THEIR USE BASF SE (DE) 2011-02-02 EP disclosed
US-20100163813-A1 Long wavelength shifted benzotriazole uv-absorbers and their use CIBA CORPORATION 2010-07-01 US disclosed
US-20100163813-A1 Long wavelength shifted benzotriazole uv-absorbers and their use CIBA CORPORATION 2010-07-01 US disclosed
US-20100163813-A1 Long wavelength shifted benzotriazole uv-absorbers and their use CIBA CORPORATION 2010-07-01 US disclosed
EP-2032577-A1 LONG WAVELENGTH SHIFTED BENZOTRIAZOLE UV-ABSORBERS AND THEIR USE Ciba Holding Inc. (CH) 2009-03-11 EP disclosed
WO-2008000646-A1 LONG WAVELENGTH SHIFTED BENZOTRIAZOLE UV-ABSORBERS AND THEIR USE CIBA HOLDING INC. (CH) 2008-01-03 WO disclosed
WO-2008000646-A1 LONG WAVELENGTH SHIFTED BENZOTRIAZOLE UV-ABSORBERS AND THEIR USE CIBA HOLDING INC. (CH) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11518764-B2 Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction BCL6, BCL6B, BCL3 SMN1; SMN2 3475/4885NPC1 406/4885RAB9A 2968/4885
US-20200331921-A1 INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF BCL6, BCL6B, BCL3 SMN1; SMN2 3429/4885NPC1 401/4885RAB9A 3117/4885
US-20100163813-A1 Long wavelength shifted benzotriazole uv-absorbers and their use SULT1A1, GABBR1, TPMT SMN1; SMN2 3455/4885NPC1 2678/4885RAB9A 4775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.